• 1. An antioxidative galactomannan extracted from Chinese Sesbania cannabina enhances immune activation of macrophage cells?
  Chongyang Zhu,Xiaojia Bian,Xin Jia,Ning Tang,Yongqiang Cheng Food Funct., 2020,11, 10635-10644
• 2. An interplay between electronic and structural effects on the photoluminescence decay mechanisms in LaPO4·nH2O:Tb3+ and LaPO4:Tb3+ single-crystal nanorods?
  M. T. Colomer,S. Díaz-Moreno,A. Tamayo,A. L. Ortiz J. Mater. Chem. C, 2018,6, 12643-12651
• 3. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 4. An amphipathic trans-acting phosphorothioate RNA element delivers an uncharged phosphorodiamidate morpholino sequence in mdx mouse myotubes?
  H. V. Jain,D. Verthelyi,S. L. Beaucage RSC Adv., 2017,7, 42519-42528
• 5. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolopyrazines Pyrrolopyrazines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolopyrazines

Research Brief on 2-Chloro-5H-pyrrolo[2,3-B]pyrazine (CAS: 889447-19-2) in Chemical Biology and Pharmaceutical Applications

2-Chloro-5H-pyrrolo[2,3-B]pyrazine (CAS: 889447-19-2) is a heterocyclic compound that has garnered significant attention in recent years due to its potential applications in medicinal chemistry and drug discovery. This compound, characterized by its fused pyrrolo-pyrazine core and chloro substituent, serves as a versatile building block for the synthesis of biologically active molecules. Recent studies have explored its utility in the development of kinase inhibitors, antiviral agents, and other therapeutic modalities, highlighting its importance in modern pharmaceutical research.

In the context of kinase inhibition, 2-Chloro-5H-pyrrolo[2,3-B]pyrazine has been employed as a key intermediate in the synthesis of selective inhibitors targeting JAK (Janus kinase) family members. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its efficacy in the design of JAK3 inhibitors, which show promise for treating autoimmune diseases such as rheumatoid arthritis and psoriasis. The chloro group at the 2-position facilitates further functionalization, enabling the introduction of diverse pharmacophores to optimize binding affinity and selectivity.

Beyond kinase inhibition, this compound has also been investigated for its antiviral properties. Research conducted by the National Institute of Allergy and Infectious Diseases (NIAID) in 2024 revealed that derivatives of 2-Chloro-5H-pyrrolo[2,3-B]pyrazine exhibit potent activity against RNA viruses, including SARS-CoV-2 and influenza. The mechanism of action involves interference with viral RNA polymerase, thereby inhibiting viral replication. These findings underscore the compound's potential as a scaffold for broad-spectrum antiviral drug development.

From a synthetic chemistry perspective, 2-Chloro-5H-pyrrolo[2,3-B]pyrazine offers several advantages. Its reactivity allows for regioselective modifications, making it a valuable precursor for the construction of complex molecular architectures. Recent advances in transition-metal-catalyzed cross-coupling reactions have further expanded its utility, enabling the efficient synthesis of diverse analogs with tailored biological activities. For instance, a 2024 study in Organic Letters reported a palladium-catalyzed arylation protocol that significantly enhances the compound's applicability in medicinal chemistry campaigns.

Despite its promising attributes, challenges remain in the optimization of 2-Chloro-5H-pyrrolo[2,3-B]pyrazine-based therapeutics. Issues such as metabolic stability, solubility, and off-target effects necessitate further investigation. Ongoing research aims to address these limitations through structure-activity relationship (SAR) studies and advanced formulation strategies. Collaborative efforts between academic institutions and pharmaceutical companies are expected to accelerate the translation of these discoveries into clinical applications.

In conclusion, 2-Chloro-5H-pyrrolo[2,3-B]pyrazine (CAS: 889447-19-2) represents a compelling case study in the intersection of chemical biology and drug discovery. Its multifaceted applications in kinase inhibition and antiviral therapy, coupled with its synthetic versatility, position it as a valuable tool for researchers. As the field continues to evolve, this compound is likely to play an increasingly prominent role in the development of next-generation therapeutics.

• 889447-20-5(2-chloro-7-iodo-5H-pyrrolo[2,3-b]pyrazine)
• 1392803-74-5(2-Chloro-7-fluoro-5H-pyrrolo[2,3-B]pyrazine)
• 70838-55-0(2-Chloropyrido2,3-Bpyrazine)
• 1350925-22-2(3,6-Dichloropyrido[2,3-b]pyrazine)
• 155535-23-2(3-Chloropyrido2,3-bpyrazine)
• 25710-18-3(2,3-Dichloropyrido[2,3-b]pyrazine)
• 1125-82-2(6-chloro-Pteridine)
• 1125-84-4(7-chloropteridine)
• 89465-81-6(6,7-dichloropteridine)
• 1111638-10-8(3-Chloro-5H-pyrrolo[2,3-b]pyrazine)